<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pone.0210937</article-id><article-id pub-id-type="publisher-id">PONE-D-17-42195</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Tropical Diseases</subject><subj-group><subject>Tuberculosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject><subj-group><subject>Children</subject><subj-group><subject>Adolescents</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Families</subject><subj-group><subject>Children</subject><subj-group><subject>Adolescents</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Immunodeficiency Viruses</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Retroviruses</subject><subj-group><subject>Lentivirus</subject><subj-group><subject>HIV</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject><subj-group><subject>Young Adults</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>HIV epidemiology</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Co-Infections</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Population Groupings</subject><subj-group><subject>Age Groups</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Public and Occupational Health</subject><subj-group><subject>Preventive Medicine</subject><subj-group><subject>Vaccination and Immunization</subject><subj-group><subject>Antiviral Therapy</subject><subj-group><subject>Antiretroviral Therapy</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town</article-title><alt-title alt-title-type="running-head">HIV and tuberculosis among urban youth in South Africa</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6840-7291</contrib-id><name><surname>Mulongeni</surname><given-names>Pancho</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Hermans</surname><given-names>Sabine</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Caldwell</surname><given-names>Judy</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bekker</surname><given-names>Linda-Gail</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>Robin</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kaplan</surname><given-names>Richard</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>The Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>School of Public Health and Community Medicine, University of New South Wales, Sydney Australia</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Global Health, Academic Medical Center, University of Amsterdam, Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>City Health, City of Cape Town, Cape Town, South Africa</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Lessells</surname><given-names>Richard John</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of KwaZulu-Natal, SOUTH AFRICA</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>p.mulongeni@student.unsw.edu.au</email></corresp></author-notes><pub-date pub-type="epub"><day>5</day><month>2</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>2</issue><elocation-id>e0210937</elocation-id><history><date date-type="received"><day>30</day><month>11</month><year>2017</year></date><date date-type="accepted"><day>4</day><month>1</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Mulongeni et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Mulongeni et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0210937.pdf"/><abstract><p>TB remains a leading cause of mortality and morbidity in sub-Saharan Africa, due to the HIV epidemic. As TB treatment is lengthy, the completion of the full course of treatment may be especially challenging for young people. We therefore aimed to identify the extent of and reasons underlying loss to follow-up from TB treatment among young people in Cape Town. Accordingly, we reviewed the outcomes of young people treated for TB in Cape Town during 2009&#x02013;2013, across three age groups: younger adolescents (10&#x02013;14 years); older adolescents; (15&#x02013;19 years) and young adults (20&#x02013;24 years). We employed logistic regression analysis to identify risk factors for loss from TB care. 23,737 patients aged 10&#x02013;24 were treated for drug sensitive TB over the study period. Of these, the HIV co-infection prevalence was 18.5% for younger adolescents, 12.9% for older adolescents and 33.1% for young adults. From age 16, HIV prevalence increased disproportionately among young women: by age 22, over 50% of women were TB/HIV co-infected compared to 14% of men. TB treatment success (cure plus completion) was 84.4%, while 1.7% of patients died, 9.5% were lost-to follow-up and 0.4% failed treatment. Being an older adolescent (aOR 1.75 [95% CI: 1.38&#x02013;2.21]) or young adult (aOR: 1.96 [95% CI: 1.57&#x02013;2.45]) increased the risk of loss-to-follow up, relative to being a younger adolescent. Further risk factors for loss from TB care were male gender (aOR: 1.33 [95% CI:1.20&#x02013;1.46]), being a TB/HIV co-infected young person (aOR 1.74 [95% CI: 1.57&#x02013;1.93]) and having had prior treatment for TB (aOR 3.17 [95% CI 2.87&#x02013;3.51]). We identified risk factors for loss to follow-up and highlighted the need to focus on HIV prevention and retention in TB care among young people. TB care tailored to the needs of young people could improve patient retention, similar to improved outcomes reported by youth friendly HIV clinics.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000866</institution-id><institution>International AIDS Vaccine Initiative</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6840-7291</contrib-id><name><surname>Mulongeni</surname><given-names>Pancho</given-names></name></principal-award-recipient></award-group><funding-statement>The study was supported by the International AIDS Vaccine Initiative (IAVI) fellowship in Adolescent Health (PM). PM received funding support as TB2016 Conference Secretariat after applying for funding (airfare, ticket and per-diem) to present her abstract at the TB2016 Conference in Durban, South Africa. SH received salary support from the European Union [Marie Curie International Outgoing Fellowship for Career Development PIOF-GA-2012-332311]. RW received salary support from the South African Medical Research Council [MRC-RFAUFSP-01-2013/CCAMP], the National Institutes of Health [R01AI058736 and R01AI093269] and the Bill &#x00026; Melinda Gates Foundation [OPP1116641].</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="4"/><page-count count="16"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>Data that support the findings of this study are publically available at the Harvard Dataverse repository, which can be retrieved at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7910/DVN/EPBBVV">https://doi.org/10.7910/DVN/EPBBVV</ext-link>.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>Data that support the findings of this study are publically available at the Harvard Dataverse repository, which can be retrieved at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7910/DVN/EPBBVV">https://doi.org/10.7910/DVN/EPBBVV</ext-link>.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>In South Africa, tuberculosis (TB) remains one of the biggest causes of death during the productive years of life [<xref rid="pone.0210937.ref001" ref-type="bibr">1</xref>]. As human immunodeficiency virus-1 (HIV) infection became widespread in South Africa, the fraction of the population with immunosuppression expanded, resulting in a rise in TB disease [<xref rid="pone.0210937.ref002" ref-type="bibr">2</xref>]. In order to treat TB patients successfully, the health services need to successfully identify and treat TB/HIV co-infection. There has been some progress in this regard, with HIV testing among TB patients increasing from 59% to 93% over the course of 2009&#x02013;14 [<xref rid="pone.0210937.ref003" ref-type="bibr">3</xref>]. However, successful TB treatment outcomes from 2012 to 2013 remained at roughly 77&#x02013;78%, which is below the national target of 82% and far from the international targets of 85&#x02013;90% [<xref rid="pone.0210937.ref003" ref-type="bibr">3</xref>].</p><p>While young people have been recognized as a priority population for the prevention of HIV [<xref rid="pone.0210937.ref004" ref-type="bibr">4</xref>], appreciation for the epidemiology of TB and the extent to which it overlaps with the HIV epidemic among young people has just begun to grow. Youthful populations face considerable challenges engaging with health services that are often tailored to adults and are insensitive to their developmental needs. Young people in particular, may have heightened difficulty remaining in TB care, because of adverse events related to treatment, as has been noted in high burden TB countries [<xref rid="pone.0210937.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0210937.ref006" ref-type="bibr">6</xref>]. Furthermore, as young people have not attained neurocognitive maturity they face&#x02014;on average&#x02014;greater difficulties in weighing the long-term consequences of their decisions compared to adults; an important consideration in understanding the reasons for which members of this population often discontinue lengthy treatment regimens [<xref rid="pone.0210937.ref007" ref-type="bibr">7</xref>]. Hence, a young person with TB may find it especially challenging to keep appointments with health providers and follow their recommendations [<xref rid="pone.0210937.ref008" ref-type="bibr">8</xref>].Youth friendly health services have been shown to increase retention in HIV treatment and Multi-Drug Resistant (MDR)-TB in sub-Saharan Africa [<xref rid="pone.0210937.ref009" ref-type="bibr">9</xref>, <xref rid="pone.0210937.ref010" ref-type="bibr">10</xref>]. Such services may potentially improve drug sensitive TB treatment outcomes among young people in South Africa, but they are not widely available.</p><p>While earlier studies have focused on the prevalence of latent TB [<xref rid="pone.0210937.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0210937.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0210937.ref012" ref-type="bibr">12</xref>] and the incidence of active TB [<xref rid="pone.0210937.ref013" ref-type="bibr">13</xref>] in an adolescent cohort in South Africa, only three prior studies have addressed the outcomes of adolescents treated for TB in the country. Two of the studies enlisted only adolescents with multidrug resistant TB [<xref rid="pone.0210937.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0210937.ref014" ref-type="bibr">14</xref>] and are therefore of limited value in understanding how young people fair on treatment for drug sensitive TB. The most recent of the studies illustrated the TB epidemic among young people in the Western Cape Province, with a focus on HIV co-infection, notification rates and loss from TB care [<xref rid="pone.0210937.ref015" ref-type="bibr">15</xref>]. Yet this study only included new TB patients over a period of one year, overlooking young people who had prior TB and thus curtailing the usefulness of the findings in fully understanding youthful TB patient populations. No study has provided a risk factor analysis of the pathways through which young people on TB treatment in South Africa prematurely stop their treatment. Therefore, the question of which factors impact on retention in TB care&#x02013;and the relationship thereof to HIV care for young people remains unanswered.</p><p>The aim of our study was to determine the burden of drug sensitive TB, across three different age groups, among young people in Cape Town and to assess TB treatment outcomes and the determinants thereof in this vulnerable group of patients. To this end, we estimated TB notification rates, prevalence of TB/HIV co-infection and determined TB treatment outcomes among younger adolescents, older adolescents and young adults. We also identified the risk factors for loss to follow-up from TB care.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Setting</title><p>Cape Town is the capital of the Western Cape Province of South Africa, and had an estimated population of approximately 3,851,163 in mid-2016 [<xref rid="pone.0210937.ref016" ref-type="bibr">16</xref>]. The city has a high prevalence of TB/HIV co-infection, with HIV prevalence among TB patients ranging between 44&#x02013;50% during 2009&#x02013;13 [<xref rid="pone.0210937.ref017" ref-type="bibr">17</xref>].</p><p>Patients with TB are treated at 101 primary care clinics across the city. Children, young people and adults with TB are treated in the same clinic, with routine TB care for ambulant patients provided by trained TB nurses. Medical officers provide supervision and support for the management of complicated cases [<xref rid="pone.0210937.ref018" ref-type="bibr">18</xref>].</p><p>Young people with TB received care in accordance with the South African national TB treatment guidelines [<xref rid="pone.0210937.ref019" ref-type="bibr">19</xref>]. Treatment duration was 6 months, with 8 months as the duration for patients with retreatment TB treated before 2012. After 2012, all drug sensitive new and retreatment TB patients received 6 months of TB treatment unless there was a clinical indication to extend the treatment duration [<xref rid="pone.0210937.ref020" ref-type="bibr">20</xref>].</p></sec><sec id="sec004"><title>Design and study population</title><p>Retrospective cohort study of all young people (aged between 10 and 24 years), treated for drug susceptible TB in Cape Town primary care TB clinics between 2009 and 2013.</p><p>Data were obtained from the electronic TB register of City Health, City of Cape Town (ETR.net). Missing values were not replaced. Patients with drug-resistant tuberculosis (DR-TB) were also not included in the analysis, as they are recorded in a separate database.</p><p>As the ETR.net database contains no identifying information, we were unable to identify instances of one patient receiving their TB treatment course across more than one facility. For this reason, all patients who transferred into a facility were removed from the database. This avoided double counting of patients who begin their TB treatment course at one facility and then continue treatment at another facility.</p></sec><sec id="sec005"><title>Data sources and measurements</title><p>For all patients, age, sex, date of treatment initiation, completion or last date of contact with health facility, type of TB (new or retreatment), anatomical site (pulmonary tuberculosis (PTB) or extrapulmonary tuberculosis (EPTB)), HIV status and TB treatment outcomes were extracted from the database. For HIV positive patients, CD4+ T-cell (CD4) count and antiretroviral therapy (ART) status at start of TB treatment were also extracted. Annual population estimates for Cape Town were obtained from mid-year estimates by Statistics South Africa [<xref rid="pone.0210937.ref016" ref-type="bibr">16</xref>].</p><sec id="sec006"><title>Definitions</title><p>HIV status was confirmed according to an algorithm that accounted for HIV test results, ART status and CD4 count, as described previously [<xref rid="pone.0210937.ref021" ref-type="bibr">21</xref>]. A patient was defined to be HIV positive in three ways: either the patient had an HIV positive result recorded in the database or the patient was on ART or co-trimoxazole prophylaxis,or had a CD4 count measurement recorded upon entry into TB care. HIV negative TB patients were those who had an HIV negative test recorded in the database. All other patients were considered to have an unknown HIV status.</p><p>We defined three age categories, younger adolescents (10&#x02013;14 years), older adolescents (15&#x02013;19 years) and young adults (20&#x02013;24 years), according to a framework proposed in a recent review of the causes of mortality and morbidity in young people [<xref rid="pone.0210937.ref004" ref-type="bibr">4</xref>].</p><p>The treatment outcomes of cure, completion, failure and transfer out followed the WHO definitions [<xref rid="pone.0210937.ref022" ref-type="bibr">22</xref>]. Treatment success was defined as the sum of cure and completion. Death comprised all-cause mortality during TB care.</p><p>Patients who interrupted TB treatment (failed to collect medications) for a period of at least 2 months were considered to have become Lost To Follow-Up. The date of loss to follow-up was defined as the last recorded date TB medications were collected. Facilities undertook efforts to trace these patients. However, in spite of efforts to recall, those patients who failed to return to care (after a period of at least 2 months) were deemed Lost to Follow-Up</p><p>In the event previous TB patients returned to TB care, after an absence of at least two months regardless of the first outcome, they were classified as retreatment cases on TB treatment re-initiation.</p></sec><sec id="sec007"><title>Data analysis</title><p>Data analysis was performed in Stata (Stata Corp 2013, Stata Statistical Software: Release 13. College Station, TX: StataCorp LP), R (The R Foundation for Statistical Computing, Version 3.2.3), using the RStudio interface (RStudio,Inc. Version 0.99.896) and Microsoft Excel 2013 (Microsoft Corp 2013).</p></sec><sec id="sec008"><title>Descriptive statistics</title><p>To estimate TB notification rates among young people in Cape Town, the annual number of TB patients per age group (from ETR.net) was divided by the age-specific population estimates for 2009&#x02013;13 [<xref rid="pone.0210937.ref016" ref-type="bibr">16</xref>]. Descriptive statistics of HIV prevalence, ART usage and TB treatment outcomes were calculated by age category.</p></sec><sec id="sec009"><title>Inferential statistics</title><p>To assess the possibility of an association between age group and EPTB in younger adolescents relative to either older adolescents or young adults, Pearson&#x02019;s Chi Squared Test statistic was computed. The Cochrane-Armitage Test was used to assess the significance of trends in the prevalence of retreatment TB, among all TB patients, in addition to the outcomes of death and loss to follow-up, across the three age categories.</p></sec><sec id="sec010"><title>Survival analysis</title><p>Events were defined as having loss to follow-up as an outcome, all other outcomes were defined as right-censored. Kaplan-Meier curves were drawn to illustrate differences in risk of loss to follow-up by age group. The log-rank test was used to test for heterogeneity in risk of loss to follow-up across age groups. Testing of the assumption of proportional hazards, by using scaled Schoenfeld residuals, was undertaken to assess the appropriateness of Cox-proportional hazards regression for modelling. Should there be sufficient evidence to reject the assumption of proportional hazards, the Cox-proportional hazards regression is rejected as a method of analysis. Logistic regression is then used as the appropriate technique to identify risk factor for loss to follow-up.</p></sec><sec id="sec011"><title>Multivariable modelling</title><p>Logistic regression analysis was performed to identify risk factors for loss from TB care for the entire cohort then separately for those adolescents living with HIV. In addition to all the co-variates in the model for the entire cohort, the model among only HIV positive adolescents included CD4+ count category and ART status at the start of TB treatment. Univariable models (with a threshold of p&#x0003c;0.05 for significance of effect size) were used to identify risk factors for inclusion in the multivariable model using backward selection.</p></sec><sec id="sec012"><title>Ethics</title><p>Approval for use of patient data was granted by City Health Directorate, City of Cape Town. The initial data collection was for a routine monitoring and evaluation process of the South African National TB Control Program rather than for an academic study. As such, patients were not asked to give informed consent for use of their clinical records. Patient confidentiality was assured by removing all identifiers from the dataset prior to use by investigators. The study was conducted in compliance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. Ethical approval for this study was obtained by the Human Research Ethics Committee at the Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.</p></sec></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Patient characteristics</title><p>During the course of 2009&#x02013;2013, a total of 23,737 adolescent and young adult patients (aged 10&#x02013;24 years) were registered for treatment of drug sensitive TB across 101 primary care health facilities in Cape Town. Of these 8.5% were younger adolescents (aged 10&#x02013;14 years), 29.7% were older adolescents (aged 15&#x02013;19 years) while young adults (20&#x02013;24 years) constituted the bulk of the patients (61.8%). Across age categories, females comprised 54.6% of the TB patients. Demographic and clinical characteristics of adolescent TB patients by age groups are shown in <xref rid="pone.0210937.t001" ref-type="table">Table 1</xref>.</p><table-wrap id="pone.0210937.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of adolescents and young adults treated for TB in Cape Town during 2009&#x02013;13.</title></caption><alternatives><graphic id="pone.0210937.t001g" xlink:href="pone.0210937.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Age category (years)</th><th align="center" rowspan="1" colspan="1">10&#x02013;14</th><th align="center" rowspan="1" colspan="1">15&#x02013;19</th><th align="center" rowspan="1" colspan="1">20&#x02013;24</th><th align="center" rowspan="1" colspan="1">Total</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">N (%)</th><th align="center" rowspan="1" colspan="1">N (%)</th><th align="center" rowspan="1" colspan="1">N (%)</th><th align="center" rowspan="1" colspan="1">N (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>All patients</bold></td><td align="center" rowspan="1" colspan="1">2017 (100%)</td><td align="center" rowspan="1" colspan="1">7046 (100%)</td><td align="center" rowspan="1" colspan="1">14674 (100%)</td><td align="center" rowspan="1" colspan="1">23737 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV status</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">HIV Negative</td><td align="center" rowspan="1" colspan="1">1536 (76.2%)</td><td align="center" rowspan="1" colspan="1">5889 (83.6%)</td><td align="center" rowspan="1" colspan="1">9393 (64.0%)</td><td align="center" rowspan="1" colspan="1">16818 (70.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">HIV Positive</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">373 (18.5%)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">909(12.9%)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">4855 (33.1%)</td><td align="center" style="background-color:#FFFFFF" rowspan="1" colspan="1">6137(25.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Unknown status</td><td align="center" rowspan="1" colspan="1">108 (5.4%)</td><td align="center" rowspan="1" colspan="1">248 (3.5%)</td><td align="center" rowspan="1" colspan="1">426 (2.9%)</td><td align="center" rowspan="1" colspan="1">782 (3.3%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Gender</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">1131 (56.1%)</td><td align="center" rowspan="1" colspan="1">3873 (55.0%)</td><td align="center" rowspan="1" colspan="1">7957 (54.2%)</td><td align="center" rowspan="1" colspan="1">12961 (54.6%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">886 (43.9%)</td><td align="center" rowspan="1" colspan="1">3173 (45.0%)</td><td align="center" rowspan="1" colspan="1">6717 (45.8%)</td><td align="center" rowspan="1" colspan="1">10776 (45.4%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Classification</td><td align="center" colspan="4" rowspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">PTB</td><td align="center" rowspan="1" colspan="1">1646 (81.6%)</td><td align="center" rowspan="1" colspan="1">6197 (88.0%)</td><td align="center" rowspan="1" colspan="1">12540 (85.5%)</td><td align="center" rowspan="1" colspan="1">20383 (85.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">EPTB</td><td align="center" rowspan="1" colspan="1">371 (18.4%)</td><td align="center" rowspan="1" colspan="1">849 (12.0%)</td><td align="center" rowspan="1" colspan="1">2134 (14.5%)</td><td align="center" rowspan="1" colspan="1">3354 (14.1%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Category</td><td align="center" colspan="4" rowspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">New TB</td><td align="center" rowspan="1" colspan="1">1914 (94.9%)</td><td align="center" rowspan="1" colspan="1">6323 (89.7%)</td><td align="center" rowspan="1" colspan="1">12146 (82.8%)</td><td align="center" rowspan="1" colspan="1">20383 (85.9%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Retreatment TB</td><td align="center" rowspan="1" colspan="1">103 (5.1%)</td><td align="center" rowspan="1" colspan="1">723 (10.3%)</td><td align="center" rowspan="1" colspan="1">2528 (17.2%)</td><td align="center" rowspan="1" colspan="1">3354 (14.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1"><bold>HIV positive patients<xref ref-type="table-fn" rid="t001fn001">*</xref></bold></td><td align="center" colspan="4" rowspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">CD4 count &#x0003c;100</td><td align="center" rowspan="1" colspan="1">68(18.2%)</td><td align="center" rowspan="1" colspan="1">156 (17.2%)</td><td align="center" rowspan="1" colspan="1">1267 (26.1%)</td><td align="center" rowspan="1" colspan="1">1491(24.3%)</td></tr><tr><td align="right" rowspan="1" colspan="1">CD4 count: 100&#x02013;199</td><td align="center" rowspan="1" colspan="1">51 (13.7%)</td><td align="center" rowspan="1" colspan="1">208 (22.9%)</td><td align="center" rowspan="1" colspan="1">1050 (21.6%)</td><td align="center" rowspan="1" colspan="1">1309 (21.3%)</td></tr><tr><td align="right" rowspan="1" colspan="1">CD4 count: 200&#x02013;349</td><td align="center" rowspan="1" colspan="1">81 (21.7%)</td><td align="center" rowspan="1" colspan="1">225 (24.8)</td><td align="center" rowspan="1" colspan="1">1169 (24.1)</td><td align="center" rowspan="1" colspan="1">1475(24.0%)</td></tr><tr><td align="right" rowspan="1" colspan="1">CD4 count: 350&#x02013;499</td><td align="center" rowspan="1" colspan="1">55 (14.7%)</td><td align="center" rowspan="1" colspan="1">151 (16.6%)</td><td align="center" rowspan="1" colspan="1">684 (14.1%)</td><td align="center" rowspan="1" colspan="1">890 (14.5%)</td></tr><tr><td align="right" rowspan="1" colspan="1">CD4 count &#x0003e; = 500</td><td align="center" rowspan="1" colspan="1">76 (20.4%)</td><td align="center" rowspan="1" colspan="1">126 (13.9%)</td><td align="center" rowspan="1" colspan="1">499 (10.3%)</td><td align="center" rowspan="1" colspan="1">701(11.4%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Unknown CD4 count</td><td align="center" rowspan="1" colspan="1">42 (11.3%)</td><td align="center" rowspan="1" colspan="1">43 (4.7%)</td><td align="center" rowspan="1" colspan="1">186 (3.8%)</td><td align="center" rowspan="1" colspan="1">271 (4.4%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Median CD4 count (IQR)</td><td align="center" rowspan="1" colspan="1">279 (131&#x02013;486)</td><td align="center" rowspan="1" colspan="1">239 (128&#x02013;391)</td><td align="center" rowspan="1" colspan="1">201 (92&#x02013;352)</td><td align="center" rowspan="1" colspan="1">210 (98&#x02013;365)</td></tr><tr><td align="right" rowspan="1" colspan="1">ART na&#x000ef;ve at start of TB Rx</td><td align="center" rowspan="1" colspan="1">255 (68.1%)</td><td align="center" rowspan="1" colspan="1">770 (84.7%)</td><td align="center" rowspan="1" colspan="1">4082 (84.1%)</td><td align="center" rowspan="1" colspan="1">5107 (83.2%)</td></tr><tr><td align="right" rowspan="1" colspan="1">On ART at start of TB Rx</td><td align="center" rowspan="1" colspan="1">118 (31.6%)</td><td align="center" rowspan="1" colspan="1">139 (15.3%)</td><td align="center" rowspan="1" colspan="1">770 (15.9%)</td><td align="center" rowspan="1" colspan="1">1027 (16.7%)</td></tr><tr><td align="right" rowspan="1" colspan="1">Unknown ART status</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">3 (0.1%)</td><td align="center" rowspan="1" colspan="1">3 (0%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>*The CD4 count and ART status at start of TB Rx refer to the 6137 HIV positive patients</p></fn><fn id="t001fn002"><p>ART, Antiretroviral Therapy; EPTB, Extrapulmonary Tuberculosis; PTB, Pulmonary Tuberculosis; Rx, treatment course.</p></fn></table-wrap-foot></table-wrap><p>Most young people presented with PTB across the age categories, with a higher fraction of EPTB patients in younger adolescents (18.4%) than in either of the older age categories (12.0% in older adolescents and 14.5% in young adults, p&#x0003c;0.001). Most adolescents had new TB, with the fraction of retreatment TB increasing steadily across the three age categories (5.1% in 10&#x02013;14 year olds, 10.3% in 15&#x02013;19 year olds and 14.3% in 20&#x02013;24 year olds, p&#x0003c;0.001).</p></sec><sec id="sec015"><title>Case Notification Rates (CNR)</title><p>The estimated CNR among adolescents over the period 2009 to 2013 are presented in <xref ref-type="fig" rid="pone.0210937.g001">Fig 1</xref>. Older age categories had higher rates of TB. Overall, CNR declined across all three age categories over the study period.</p><fig id="pone.0210937.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.g001</object-id><label>Fig 1</label><caption><title>Trends in case notification rates per 100 000 population by age group, in Cape Town.</title></caption><graphic xlink:href="pone.0210937.g001"/></fig></sec><sec id="sec016"><title>TB/HIV co-infection</title><p>The prevalence of TB/HIV co-infection was highest among young adults (33.1%), followed by younger adolescents (18.5%) and older adolescents (12.9%) (<xref rid="pone.0210937.t001" ref-type="table">Table 1</xref>). When disaggregating these age groups into individual age year bands, the rise of HIV prevalence with age was apparent (Figs <xref ref-type="fig" rid="pone.0210937.g002">2</xref> and <xref ref-type="fig" rid="pone.0210937.g003">3</xref>). Starting from the age of 16, there was a steady increase in HIV prevalence in young women with TB. By the age of 22 more than 50% were HIV co-infected (<xref ref-type="fig" rid="pone.0210937.g002">Fig 2</xref>), in contrast to 14% among young men with TB (<xref ref-type="fig" rid="pone.0210937.g003">Fig 3</xref>). The median CD4 count among HIV co-infected adolescents at start of TB treatment was highest in younger adolescents and was markedly lower in the older age groups.</p><fig id="pone.0210937.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.g002</object-id><label>Fig 2</label><caption><title>Prevalence of TB/HIV co-infection, across age categories, for female adolescents and young women treated for TB in Cape Town during 2009&#x02013;13.</title></caption><graphic xlink:href="pone.0210937.g002"/></fig><fig id="pone.0210937.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.g003</object-id><label>Fig 3</label><caption><title>Prevalence of TB/HIV co-infection, across age categories, for male adolescents and young men treated for TB in Cape Town during 2009&#x02013;13.</title></caption><graphic xlink:href="pone.0210937.g003"/></fig><p>Furthermore, the proportion of TB/HIV co-infected young people who were on ART at the start of TB treatment was largest in the younger adolescents (31.6%), roughly double that of older adolescents and young adults on ART on entering TB care (<xref rid="pone.0210937.t001" ref-type="table">Table 1</xref>). Over the course of the study period, the proportion of TB/HIV co-infected young people who were already enrolled in ART care at the time of enrolment in TB care increased across all age groups despite fluctuations in this fraction from one year to the next (<xref ref-type="fig" rid="pone.0210937.g004">Fig 4</xref>). Overall, among all HIV positive adolescents and young adults, the increase was from 8% on ART at time of enrolment in 2009 to 27% in 2013.</p><fig id="pone.0210937.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.g004</object-id><label>Fig 4</label><caption><title>Proportion of younger adolescents, older adolescents and young adults with TB/HIV coinfection on ART at start of TB treatment per calendar year.</title></caption><graphic xlink:href="pone.0210937.g004"/></fig></sec><sec id="sec017"><title>TB treatment outcomes</title><p>The TB treatment outcomes are shown in <xref rid="pone.0210937.t002" ref-type="table">Table 2</xref>. TB treatment success rates ranged from 82.0% in young adults to 92.0% in younger adolescents. High success rates in the younger age categories were commensurate with lower rates of loss to follow-up, with 1 in 20 younger adolescents becoming lost to follow-up on treatment compared to 1 in 9 young adults (p&#x0003c;0.001). Mortality also increased with age group, increasing from 0.5% in younger adolescents to 2.2% in young adults (p&#x0003c;0.001).</p><table-wrap id="pone.0210937.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.t002</object-id><label>Table 2</label><caption><title>TB treatment outcomes of adolescent and young adult TB patients.</title></caption><alternatives><graphic id="pone.0210937.t002g" xlink:href="pone.0210937.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">10&#x02013;14 years</th><th align="left" rowspan="1" colspan="1">15&#x02013;19 years</th><th align="left" rowspan="1" colspan="1">20&#x02013;24 years</th><th align="left" rowspan="1" colspan="1">Total</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total, n</td><td align="left" rowspan="1" colspan="1">2017 (100%)</td><td align="left" rowspan="1" colspan="1">7046 (100%)</td><td align="left" rowspan="1" colspan="1">14674 (100%)</td><td align="left" rowspan="1" colspan="1">23737 (100%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Cure plus completion, n (%)</td><td align="left" rowspan="1" colspan="1">1858 (92.0%)</td><td align="left" rowspan="1" colspan="1">6143 (87.2%)</td><td align="left" rowspan="1" colspan="1">12033 (82.0%)</td><td align="left" rowspan="1" colspan="1">20034 (84.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Loss to follow-up, n (%)</td><td align="left" rowspan="1" colspan="1">90 (4.5%)</td><td align="left" rowspan="1" colspan="1">570 (8.1%)</td><td align="left" rowspan="1" colspan="1">1596 (10.9%)</td><td align="left" rowspan="1" colspan="1">2256 (9.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Died, n (%)</td><td align="left" rowspan="1" colspan="1">10 (0.5%)</td><td align="left" rowspan="1" colspan="1">67 (1%)</td><td align="left" rowspan="1" colspan="1">328 (2.2%)</td><td align="left" rowspan="1" colspan="1">405 (1.7%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Failed, n (%)</td><td align="left" rowspan="1" colspan="1">6 (0.3%)</td><td align="left" rowspan="1" colspan="1">26 (0.4%)</td><td align="left" rowspan="1" colspan="1">71 (0.5%)</td><td align="left" rowspan="1" colspan="1">103 (0.4%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Moved or transferred, n (%)</td><td align="left" rowspan="1" colspan="1">32 (1.6%)</td><td align="left" rowspan="1" colspan="1">140 (2.0%)</td><td align="left" rowspan="1" colspan="1">445 (3.0%)</td><td align="left" rowspan="1" colspan="1">617 (2.6%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Not evaluated, n (%)</td><td align="left" rowspan="1" colspan="1">21 (1%)</td><td align="left" rowspan="1" colspan="1">100 (1.4%)</td><td align="left" rowspan="1" colspan="1">201 (1.4%)</td><td align="left" rowspan="1" colspan="1">322 (1.4%)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>n, number.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>Survival analysis</title><p>The Kaplan-Meier curves present differences in retention in care during the course of TB treatment among young people according to age group. Young adults were more likely to become lost to follow-up relative to older and younger adolescents (<xref ref-type="fig" rid="pone.0210937.g005">Fig 5</xref>) (p&#x0003c;0.001).</p><fig id="pone.0210937.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.g005</object-id><label>Fig 5</label><caption><title>Kaplan Meier survival curve for loss to follow-up among young people in TB care by age group.</title></caption><graphic xlink:href="pone.0210937.g005"/></fig></sec><sec id="sec019"><title>Associations with loss to follow-up</title><p>Multivariable logistic regression of risk factors for loss to follow-up during TB care of young people was performed and is shown for the entire cohort, in <xref rid="pone.0210937.t003" ref-type="table">Table 3</xref>, and for TB/HIV co-infected patients, in <xref rid="pone.0210937.t004" ref-type="table">Table 4</xref>.</p><table-wrap id="pone.0210937.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.t003</object-id><label>Table 3</label><caption><title>Associations with loss to follow-up from TB treatment for the entire cohort.</title></caption><alternatives><graphic id="pone.0210937.t003g" xlink:href="pone.0210937.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Covariates</th><th align="left" rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Age</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">10&#x02013;14 year olds</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">15&#x02013;19 year olds</td><td align="center" rowspan="1" colspan="1">1.88 (1.5&#x02013;2.37)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.75 (1.38&#x02013;2.21)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="right" rowspan="1" colspan="1">20&#x02013;24 year olds</td><td align="center" rowspan="1" colspan="1">2.61 (2.10&#x02013;3.25)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.96 (1.57&#x02013;2.45)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Gender</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1.50 (1.05&#x02013;1.25)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.33 (1.20&#x02013;1.46)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">HIV status<break/></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Negative</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Positive</td><td align="center" rowspan="1" colspan="1">1.75 (1.60&#x02013;1.93)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.74 (1.57&#x02013;1.93)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>TB classification</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Pulmonary</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">EPTB</td><td align="center" rowspan="1" colspan="1">0.72 (0.62&#x02013;0.82)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">0.80 (0.69&#x02013;0.93)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Past history of TB</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">New TB</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Retreatment of TB</td><td align="center" rowspan="1" colspan="1">3.53 (3.20&#x02013;3.89)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">3.17 (2.87&#x02013;3.51)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>EPTB, Extrapulmonary Tuberculosis; OR, odds ratio; PTB, Pulmonary Tuberculosis</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0210937.t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0210937.t004</object-id><label>Table 4</label><caption><title>Associations with loss to follow-up from TB treatment for the HIV positive cohort.</title></caption><alternatives><graphic id="pone.0210937.t004g" xlink:href="pone.0210937.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Covariates</th><th align="left" rowspan="1" colspan="1">Unadjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">P-value</th><th align="left" rowspan="1" colspan="1">Adjusted OR (95% CI)</th><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>Age</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">10&#x02013;14 year olds</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">15&#x02013;19 year olds</td><td align="center" rowspan="1" colspan="1">1.95 (1.26&#x02013;3.01)</td><td align="center" rowspan="1" colspan="1">0.003</td><td align="center" rowspan="1" colspan="1">1.85 (1.17&#x02013;2.91)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="right" rowspan="1" colspan="1">20&#x02013;24 year olds</td><td align="center" rowspan="1" colspan="1">2.05 (1.38&#x02013;3.06)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">1.88 (1.23&#x02013;2.85)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Gender</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">1.19 (1.00&#x02013;1.42)</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">1.27 (1.06&#x02013;1.52)</td><td align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4 counts<xref ref-type="table-fn" rid="t004fn001">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">&#x0003c;100</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">100&#x02013;199</td><td align="center" rowspan="1" colspan="1">1.07 (0.86&#x02013;1.34)</td><td align="center" rowspan="1" colspan="1">0.54</td><td align="center" rowspan="1" colspan="1">1.13 (0.91&#x02013;1.43)</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="right" rowspan="1" colspan="1">200&#x02013;349</td><td align="center" rowspan="1" colspan="1">1.22 (0.99&#x02013;1.51)</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">1.30 (1.05&#x02013;1.61)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="right" rowspan="1" colspan="1">350&#x02013;499</td><td align="center" rowspan="1" colspan="1">0.99 (0.77&#x02013;1.28)</td><td align="center" rowspan="1" colspan="1">0.93</td><td align="center" rowspan="1" colspan="1">1.04 (0.81&#x02013;1.35)</td><td align="center" rowspan="1" colspan="1">0.74</td></tr><tr><td align="right" rowspan="1" colspan="1">&#x0003e; = 500</td><td align="center" rowspan="1" colspan="1">1.28 (0.98&#x02013;1.65)</td><td align="center" rowspan="1" colspan="1">0.07</td><td align="center" rowspan="1" colspan="1">1.34 (1.03&#x02013;1.75)</td><td align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td align="right" rowspan="1" colspan="1">ART na&#x000ef;ve at start of TB treatment</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">on ART at start of TB treatment</td><td align="center" rowspan="1" colspan="1">0.89 (0.73&#x02013;1.09)</td><td align="center" rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">0.89 (0.72&#x02013;1.75)</td><td align="center" rowspan="1" colspan="1">0.27</td></tr><tr><td align="right" rowspan="1" colspan="1">Pulmonary TB</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">EPTB</td><td align="center" rowspan="1" colspan="1">0.86 (0.71&#x02013;1.04)</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.97 (0.80&#x02013;1.18)</td><td align="center" rowspan="1" colspan="1">0.80</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Past history of TB</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">New TB</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="right" rowspan="1" colspan="1">Retreatment of TB</td><td align="center" rowspan="1" colspan="1">2.24 (1.90&#x02013;2.64)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td align="center" rowspan="1" colspan="1">2.23 (1.88&#x02013;2.65)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p>*Refers to CD4 count at time of enrolment in TB care</p></fn><fn id="t004fn002"><p>ART, Antiretroviral Therapy; EPTB, Extrapulmonary Tuberculosis; OR, odds ratio</p></fn></table-wrap-foot></table-wrap><p>In the entire cohort, there was evidence to suggest an association between several risk factors included in the model and loss to follow-up (<xref ref-type="supplementary-material" rid="pone.0210937.s001">S1 Table</xref><bold>)</bold>. Having had a previous TB episode, relative to a new episode, had the largest effect size (a roughly threefold increase in relative odds) of all factors included. Young adults had a nearly two-fold increase in relative odds of loss to follow-up compared to younger adolescents. Being HIV-positive, compared to HIV-negative, and being an older adolescent, relative to being a young adolescent, were each associated with an increase in relative odds of loss to follow-up by roughly 75%. Male patients had a roughly one-third increased relative odds of loss to follow-up compared to female patients. In contrast to these trends, patients with EPTB had a one-fifth lower relative odds of loss to follow-up compared to patients with PTB (<xref rid="pone.0210937.t003" ref-type="table">Table 3</xref>).</p><p>In the TB/HIV co-infected cohort, evidence also suggested a similar pattern of loss-to-follow up to that of the entire cohort (<xref ref-type="supplementary-material" rid="pone.0210937.s002">S2 Table</xref>). Importantly, we found no significant association between being on ART at start of TB treatment and odds of loss to follow-up in the TB/HIV co-infected cohort (aOR 0.89 (95% CI: 0.72&#x02013;1.75) (<xref rid="pone.0210937.t004" ref-type="table">Table 4</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec020"><title>Discussion</title><p>We have presented data on the burden of TB disease, TB treatment outcomes and the degree of TB/HIV co-infection among young people in Cape Town, during 2009&#x02013;2013. In addition, our study elucidates risk factors for loss to follow-up from TB care among this vulnerable population. Outside South Africa there are few studies from resource-limited settings on TB treatment outcomes among young people. Studies from Brazil and India have assessed clinical features of young people with TB [<xref rid="pone.0210937.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0210937.ref025" ref-type="bibr">25</xref>], with little reference to treatment outcomes. Our study follows on that of young people with TB in the Western Cape to provide a population-level analysis of TB treatment outcomes and TB/HIV co-infection among adolescents with active TB disease [<xref rid="pone.0210937.ref015" ref-type="bibr">15</xref>]. However, unlike the former study, we conducted an exhaustive analysis to illustrate both sex and age distribution of TB/HIV coinfection, as well as elucidating possible pathways through which adolescents and young adults become vulnerable to loss from TB care.</p><p>In Cape Town, the overall annual estimates of TB rates per 100 000 population lie between 850 in 2009 and 700 in 2013 [<xref rid="pone.0210937.ref017" ref-type="bibr">17</xref>]. These are higher than our estimates of the TB rates among younger and older adolescents. However, the estimates of the TB notification rates among young adults (aged 20&#x02013;24 years) from this study are higher than the overall Cape Town annual estimates and greater than those reported for entire Western Cape, of which Cape Town is the largest city. These results indicate that young adults in Cape Town have a higher burden of TB than the average burden for the entire province. However, differences in calculation of notification rates between our study and that of the entire province render comparisons between notifications difficult, especially since we included retreatment patients. In summary, these results identify that young adults are a vulnerable group for TB disease in Cape Town.</p><p>Earlier studies on treatment outcomes for young people in TB care have failed to identify a consistent trend between age and loss to follow up. Similar to our study, Lotfian et al. reported on outcomes of adolescent TB patients in Iran and did not find differences in loss- to-follow-up between younger and older adolescents. However the small sample size of that study precluded investigators from performing the statistical modelling required to identify independent risk factors for loss-to-follow up [<xref rid="pone.0210937.ref026" ref-type="bibr">26</xref>]. In addition, a study in India found no loss to follow-up in their sample of young people in TB care, but here too the small sample size of the study, in comparison to the large adolescent population at risk of TB disease in that country, means the findings are unlikely to be generalizable[<xref rid="pone.0210937.ref027" ref-type="bibr">27</xref>]. However a recent study from Botswana that employed a substantial sample of young people in TB care, found higher loss to follow-up among adolescents (10&#x02013;19 years of age), compared to young people (20&#x02013;24 years of age) and adults (older than 24 years) [<xref rid="pone.0210937.ref028" ref-type="bibr">28</xref>]. In contrast, Snow et al., illustrated that older adolescents (15&#x02013;19 years of age) and young adults (20&#x02013;24 years of age) had markedly higher proportions of loss-to-follow-up, relative to younger adolescents (10&#x02013;19 years of age) in the Western Cape. Noting that our study drew on a TB population in Cape Town, the largest city in the Western Cape, it corroborates that reported by Snow et al.</p><p>The corollary of what our data suggest to be an age-gradient in loss to follow-up, is that the factors that promote persistence in TB care during childhood may wane during adolescence and young adulthood. As children enter adolescence, they commonly, though not always, rebel against parental supervision, favour short term gain over long term benefit and often engage in activities that increase their socialization. They also seek employment and leave home, all of which make them vulnerable to being lost from care [<xref rid="pone.0210937.ref029" ref-type="bibr">29</xref>&#x02013;<xref rid="pone.0210937.ref032" ref-type="bibr">32</xref>]. In their study on adolescents attending TB clinics in Botswana, Enane et al. did not distinguish younger adolescents (10&#x02013;14 years old) from older adolescents (15&#x02013;19 years old) [<xref rid="pone.0210937.ref028" ref-type="bibr">28</xref>]. Therefore, one reason for the discrepancy between their findings with our data and that of Snow et al., is that the grouping of younger adolescents with their older counterparts may have masked the age dependent risk of loss from TB care that occurs during adolescence. Alternatively, owing to the large variation in distribution of factors that hinder the wellbeing of young people across countries, loss to follow-up from TB care in Botswana need not occur via the same risk pathways as in Cape Town [<xref rid="pone.0210937.ref004" ref-type="bibr">4</xref>].</p><p>Retreatment TB emerged from the data as the largest independent predictor of loss to follow-up among young people in TB care. These findings imply that young people who became lost to follow-up may have had prior TB treatment, but either failed to complete it or had a new TB infection. In the former scenario young people could be failing to complete their treatment the first time round and returning to TB care after each failed episode, each carrying a higher chance of dropping out of TB care yet again. While the consequences of this for selection of DR-TB have not been investigated, they are possibly substantial.</p><p>We found that young men in Cape Town were more likely to become lost to follow-up from TB care than young women. Therefore, male gender may promote higher loss to follow-up in young people in Cape Town, as current evidence suggests that male individuals have reduced access to and engagement with TB care services in resource limited settings [<xref rid="pone.0210937.ref033" ref-type="bibr">33</xref>].</p><p>Our study showed that young women with TB bear a disproportionate burden of TB/HIV co-infection, as TB/HIV coinfection in young women in Cape Town exceeded 50%, well above the 27% coinfection prevalence reported among all young adult TB patients in the entire Western Cape [<xref rid="pone.0210937.ref015" ref-type="bibr">15</xref>]. As this finding reflects the entire cohort of young people treated for TB, with a 95&#x02013;97% HIV testing result across age-groups, we can rule out selection bias as the source of this result. Hence the relatively higher burden of HIV prevalence among young women with TB is likely due to earlier sexually acquired HIV infection among young women relative to young men; a trend well established in sub-Saharan Africa [<xref rid="pone.0210937.ref034" ref-type="bibr">34</xref>], with a previous review identifying a peak in HIV infection among female TB patients in the 15&#x02013;24 age group among Zambian and Kenyan cohorts [<xref rid="pone.0210937.ref035" ref-type="bibr">35</xref>].</p><p>Moreover, the higher burden of HIV infection among young women likely results in more female than male TB disease among young people. An earlier prospective study on risk factors for TB disease among adolescents (aged 12&#x02013;18) in the Western Cape found female adolescents to have a 70% higher relative incidence rate of disease than male adolescents [<xref rid="pone.0210937.ref013" ref-type="bibr">13</xref>]. However, this association lacked statistical significance and HIV prevalence among incident cases was less than 1.0%. In light of our findings, prior HIV infection may drive markedly higher rates of TB in young women, which that study may have missed due to presumably low HIV risk in their population. Further research is necessary to understand how gender affects risk of TB disease among young people in resource limited settings.</p><p>A shortcoming of our analysis was that we could not ascertain the outcomes of all TB patients. In particular, patients who were reported as having transferred between health facilities, like those with outcome of &#x0201c;not evaluated&#x0201d; have no record of having either completed or discontinued TB care. This may have led to the systematic exclusion of patients at high risk for default, especially those who discontinue care after switching health facilities. However, as less than 3% of the cohort had the outcome of moving between health facilities during TB treatment and only 1.4% with outcome &#x0201c;not evaluated&#x0201d;, the impact thereof on our findings is not likely to have been substantial. The largest limitation of our study was the inability to ascertain data on occurrence and associations of DR-TB in this cohort, due to migration of all young people who develop DR-TB to a separate&#x02013;and unlinked&#x02013;database. This is a result of the current operational procedures of TB patient data collection in Cape Town, which similarly lacks linkage to HIV viral load data for patients with TB/HIV coinfection. Therefore, our study was unable to report on virological suppression for this patient population. Finally, our study lacks a much-needed assessment of the socio-political determinants of health and their role in TB treatment outcomes.</p><p>In the final analysis, our study showed a higher proportion of young women p with TB, driven by their disproportionate HIV prevalence relative to young men. We also identified increasing age, male gender, retreatment TB and TB/HIV co-infection as risk factors for increased loss to follow-up during TB treatment. The study highlights the need to focus on HIV prevention and retention in TB care among young people and reiterates the importance of addressing gender disparities in TB care [<xref rid="pone.0210937.ref036" ref-type="bibr">36</xref>]. We also emphasize the need for interventions that address TB/HIV co-infection, as young people co-infected with TB/HIV are particularly vulnerable to loss to follow-up. We support recommendations [<xref rid="pone.0210937.ref015" ref-type="bibr">15</xref>] for the introduction of adolescent tailored TB care that could improve patient retention in TB care, similar to improved outcomes reported by youth friendly HIV clinics.</p></sec><sec sec-type="supplementary-material" id="sec021"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0210937.s001"><label>S1 Table</label><caption><title>Loss to follow-up among all adolescent and young adult TB patients across co-variates in multivariable logistic regression model.</title><p>(DOCX)</p></caption><media xlink:href="pone.0210937.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0210937.s002"><label>S2 Table</label><caption><title>Loss to follow-up among HIV positive adolescent and young adult TB patients across co-variates in the multivariable logistic regression model.</title><p>(DOCX)</p></caption><media xlink:href="pone.0210937.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>This study was performed in collaboration with the Cape Town City Health Directorate.</p><p>The authors thank the TB and Leprosy Programme of the Ministry of Health and Social Services of Namibia, for giving PM their support while writing up the manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0210937.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Mahomed</surname><given-names>H</given-names></name>, <name><surname>Ehrlich</surname><given-names>R</given-names></name>, <name><surname>Hawkridge</surname><given-names>T</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Geiter</surname><given-names>L</given-names></name>, <name><surname>Kafaar</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Screening for TB in high school adolescents in a high burden setting in South Africa</article-title>. <source>Tuberculosis</source>. <year>2013</year>;<volume>93</volume>(<issue>3</issue>):<fpage>357</fpage>&#x02013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2013.02.007</pub-id> WOS:000317183000015; <?supplied-pmid 23477938?><pub-id pub-id-type="pmid">23477938</pub-id></mixed-citation></ref><ref id="pone.0210937.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Karim</surname><given-names>SSA</given-names></name>, <name><surname>Churchyard</surname><given-names>GJ</given-names></name>, <name><surname>Karim</surname><given-names>QA</given-names></name>, <name><surname>Lawn</surname><given-names>SD</given-names></name>. <article-title>HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response</article-title>. <source>Lancet</source>. <year>2009</year>;<volume>374</volume>(<issue>9693</issue>):<fpage>921</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(09)60916-8</pub-id>
<?supplied-pmid 19709731?><pub-id pub-id-type="pmid">19709731</pub-id></mixed-citation></ref><ref id="pone.0210937.ref003"><label>3</label><mixed-citation publication-type="book"><name><surname>Loveday</surname><given-names>M</given-names></name>, <name><surname>Vanleeuw</surname><given-names>L</given-names></name>. <chapter-title>Tuberculosis</chapter-title>
<source>District Health Barometer 2014/15</source>. <edition>10th ed</edition>
<publisher-loc>Durban</publisher-loc>: <publisher-name>Health Systems Trust</publisher-name>; <year>2015</year>.</mixed-citation></ref><ref id="pone.0210937.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Mokdad</surname><given-names>AH</given-names></name>, <name><surname>Forouzanfar</surname><given-names>MH</given-names></name>, <name><surname>Daoud</surname><given-names>F</given-names></name>, <name><surname>Mokdad</surname><given-names>AA</given-names></name>, <name><surname>El Bcheraoui</surname><given-names>C</given-names></name>, <name><surname>Moradi-Lakeh</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Global burden of diseases, injuries, and risk factors for young people's health during 1990&#x02013;2013: a systematic analysis for the Global Burden of Disease Study 2013</article-title>. <source>Lancet</source>. <year>2016</year>
<pub-id pub-id-type="doi">10.1016/S0140-6736(16)00648-6</pub-id></mixed-citation></ref><ref id="pone.0210937.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Isaakidis</surname><given-names>P</given-names></name>, <name><surname>Paryani</surname><given-names>R</given-names></name>, <name><surname>Khan</surname><given-names>S</given-names></name>, <name><surname>Mansoor</surname><given-names>H</given-names></name>, <name><surname>Manglani</surname><given-names>M</given-names></name>, <name><surname>Valiyakath</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Poor Outcomes in a Cohort of HIV-Infected Adolescents Undergoing Treatment for Multidrug-Resistant Tuberculosis in Mumbai, India</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>7</issue>). <pub-id pub-id-type="doi">10.1371/journal.pone.0068869</pub-id> WOS:000322391400028; <?supplied-pmid 23894358?><pub-id pub-id-type="pmid">23894358</pub-id></mixed-citation></ref><ref id="pone.0210937.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Moyo</surname><given-names>S</given-names></name>, <name><surname>Furin</surname><given-names>JJ</given-names></name>, <name><surname>Hughes</surname><given-names>J</given-names></name>, <name><surname>Daniels</surname><given-names>J</given-names></name>, <name><surname>Snyman</surname><given-names>L</given-names></name>, <name><surname>Muller</surname><given-names>O</given-names></name>, <etal>et al</etal>
<article-title>Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008&#x02013;2013</article-title>. <source>Arch Pediatr Infect Dis</source>. <year>2015</year>;<volume>3</volume>(<issue>1 TB</issue>). <pub-id pub-id-type="doi">10.5812/pedinfect.17934</pub-id></mixed-citation></ref><ref id="pone.0210937.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Shaw</surname><given-names>RJ</given-names></name>. <article-title>Treatment adherence in adolescents: Development and psychopathology</article-title>. <source>Clin Child Psychol Psychiatry</source>. <year>2001</year>;<volume>6</volume>(<issue>1</issue>):<fpage>137</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1177/1359104501006001011</pub-id></mixed-citation></ref><ref id="pone.0210937.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Dean</surname><given-names>AJ</given-names></name>, <name><surname>Walters</surname><given-names>J</given-names></name>, <name><surname>Hall</surname><given-names>A</given-names></name>. <article-title>A systematic review of interventions to enhance medication adherence in children and adolescents with chronic illness</article-title>. <source>Arch Dis Child</source>. <year>2010</year>;<volume>95</volume>(<issue>9</issue>):<fpage>717</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1136/adc.2009.175125</pub-id>
<?supplied-pmid 20522463?><pub-id pub-id-type="pmid">20522463</pub-id></mixed-citation></ref><ref id="pone.0210937.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Lamb</surname><given-names>MR</given-names></name>, <name><surname>Fayorsey</surname><given-names>R</given-names></name>, <name><surname>Nuwagaba-Biribonwoha</surname><given-names>H</given-names></name>, <name><surname>Viola</surname><given-names>V</given-names></name>, <name><surname>Mutabazi</surname><given-names>V</given-names></name>, <name><surname>Alwar</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>High attrition before and after ART initiation among youth (15&#x02013;24 years of age) enrolled in HIV care</article-title>. <source>AIDS (London, England)</source>. <year>2014</year>;<volume>28</volume>(<issue>4</issue>):<fpage>559</fpage>
<pub-id pub-id-type="doi">10.1097/QAD.0000000000000054</pub-id>
<?supplied-pmid 24076661?><pub-id pub-id-type="pmid">24076661</pub-id></mixed-citation></ref><ref id="pone.0210937.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Reif</surname><given-names>LK</given-names></name>, <name><surname>Bertrand</surname><given-names>R</given-names></name>, <name><surname>Benedict</surname><given-names>C</given-names></name>, <name><surname>Lamb</surname><given-names>MR</given-names></name>, <name><surname>Rouzier</surname><given-names>V</given-names></name>, <name><surname>Verdier</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Impact of a youth-friendly HIV clinic: 10 years of adolescent outcomes in Port-au-Prince</article-title>, <source>Haiti. J Int AIDS Soc</source>. <year>2016</year>;<volume>19</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.7448/IAS.19.1.20859</pub-id>
<?supplied-pmid 27389256?><pub-id pub-id-type="pmid">27389256</pub-id></mixed-citation></ref><ref id="pone.0210937.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Mahomed</surname><given-names>H</given-names></name>, <name><surname>Hawkridge</surname><given-names>T</given-names></name>, <name><surname>Verver</surname><given-names>S</given-names></name>, <name><surname>Geiter</surname><given-names>L</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Abrahams</surname><given-names>D</given-names></name>, <etal>et al</etal>
<article-title>Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2011</year>;<volume>15</volume>(<issue>3</issue>):<fpage>331</fpage>&#x02013;<lpage>6</lpage>. <?supplied-pmid 21333099?><pub-id pub-id-type="pmid">21333099</pub-id></mixed-citation></ref><ref id="pone.0210937.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Middelkoop</surname><given-names>K</given-names></name>, <name><surname>Bekker</surname><given-names>L-G</given-names></name>, <name><surname>Liang</surname><given-names>H</given-names></name>, <name><surname>Aquino</surname><given-names>LD</given-names></name>, <name><surname>Sebastian</surname><given-names>E</given-names></name>, <name><surname>Myer</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>Force of tuberculosis infection among adolescents in a high HIV and TB prevalence community: a cross-sectional observation study</article-title>. <source>BMC Infect Dis</source>. <year>2011</year>;<volume>11</volume>(<issue>1</issue>):<fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2334-11-156</pub-id>
<?supplied-pmid 21631918?><pub-id pub-id-type="pmid">21199579</pub-id></mixed-citation></ref><ref id="pone.0210937.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Mahomed</surname><given-names>H</given-names></name>, <name><surname>Ehrlich</surname><given-names>R</given-names></name>, <name><surname>Hawkridge</surname><given-names>T</given-names></name>, <name><surname>Hatherill</surname><given-names>M</given-names></name>, <name><surname>Geiter</surname><given-names>L</given-names></name>, <name><surname>Kafaar</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>TB incidence in an adolescent cohort in South Africa. PLoS One</article-title>. <year>2013</year>;<volume>8</volume>(<issue>3</issue>):<fpage>e59652</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0059652</pub-id>
<?supplied-pmid 23533639?><pub-id pub-id-type="pmid">23533639</pub-id></mixed-citation></ref><ref id="pone.0210937.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Seddon</surname><given-names>JA</given-names></name>, <name><surname>Hesseling</surname><given-names>AC</given-names></name>, <name><surname>Willemse</surname><given-names>M</given-names></name>, <name><surname>Donald</surname><given-names>PR</given-names></name>, <name><surname>Schaaf</surname><given-names>HS</given-names></name>. <article-title>Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome</article-title>. <source>Clin Infect Dis</source>. <year>2012</year>;<volume>54</volume>(<issue>2</issue>):<fpage>157</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cir772</pub-id>
<?supplied-pmid 22052896?><pub-id pub-id-type="pmid">22052896</pub-id></mixed-citation></ref><ref id="pone.0210937.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Snow</surname><given-names>K</given-names></name>, <name><surname>Hesseling</surname><given-names>A</given-names></name>, <name><surname>Naidoo</surname><given-names>P</given-names></name>, <name><surname>Graham</surname><given-names>S</given-names></name>, <name><surname>Denholm</surname><given-names>J</given-names></name>, <name><surname>du Preez</surname><given-names>K</given-names></name>. <article-title>Tuberculosis in adolescents and young adults: epidemiology and treatment outcomes in the Western Cape</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2017</year>;<volume>21</volume>(<issue>6</issue>):<fpage>651</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.16.0866</pub-id>
<?supplied-pmid 28482959?><pub-id pub-id-type="pmid">28482959</pub-id></mixed-citation></ref><ref id="pone.0210937.ref016"><label>16</label><mixed-citation publication-type="other">Population Estimates 2001&#x02013;2016. Statistics South Africa, 2010 Available from.<ext-link ext-link-type="uri" xlink:href="http://indicators.hst.org.za/indicators/Population/">http://indicators.hst.org.za/indicators/Population/</ext-link></mixed-citation></ref><ref id="pone.0210937.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Hermans</surname><given-names>S</given-names></name>, <name><surname>Boulle</surname><given-names>A</given-names></name>, <name><surname>Caldwell</surname><given-names>J</given-names></name>, <name><surname>Pienaar</surname><given-names>D</given-names></name>, <name><surname>Wood</surname><given-names>R</given-names></name>. <article-title>Temporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis</article-title>. <source>J Int AIDS Soc</source>. <year>2015</year>;<volume>18</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.7448/IAS.18.1.20240</pub-id>
<?supplied-pmid 26411694?><pub-id pub-id-type="pmid">26411694</pub-id></mixed-citation></ref><ref id="pone.0210937.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>R</given-names></name>, <name><surname>Caldwell</surname><given-names>J</given-names></name>, <name><surname>Hermans</surname><given-names>S</given-names></name>, <name><surname>Adriaanse</surname><given-names>S</given-names></name>, <name><surname>Mtwisha</surname><given-names>L</given-names></name>, <name><surname>Bekker</surname><given-names>L</given-names></name>, <etal>et al</etal>
<article-title>An integrated community TB-HIV adherence model provides an alternative to DOT for tuberculosis patients in Cape Town</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2016</year>;<volume>20</volume>(<issue>9</issue>):<fpage>1185</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.15.0855</pub-id>
<?supplied-pmid 27510244?><pub-id pub-id-type="pmid">27510244</pub-id></mixed-citation></ref><ref id="pone.0210937.ref019"><label>19</label><mixed-citation publication-type="other">National Tuberculosis Management Guidelines. Pretoria: Department of Health, Republic of South Africa, 2009 Available from.<ext-link ext-link-type="uri" xlink:href="http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx">http://familymedicine.ukzn.ac.za/Libraries/Guidelines_Protocols/TB_Guidelines_2009.sflb.ashx</ext-link></mixed-citation></ref><ref id="pone.0210937.ref020"><label>20</label><mixed-citation publication-type="book"><chapter-title>Circular No: H22/2013: Management and treatment of TB in adults and children older than 8 years</chapter-title>
<publisher-loc>Cape Town</publisher-loc>: <publisher-name>Western Cape Department of Health</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="pone.0210937.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Kaplan</surname><given-names>R</given-names></name>, <name><surname>Caldwell</surname><given-names>J</given-names></name>, <name><surname>Middelkoop</surname><given-names>K</given-names></name>, <name><surname>Bekker</surname><given-names>L-G</given-names></name>. <article-title>The impact of ART on TB case fatality stratified by CD4 count for HIV-positive TB patients in Cape Town, South Africa (2009&#x02013;2011)</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2014</year>;<volume>66</volume>(<issue>5</issue>):<fpage>487</fpage>
<pub-id pub-id-type="doi">10.1097/QAI.0000000000000201</pub-id>
<?supplied-pmid 24820105?><pub-id pub-id-type="pmid">24820105</pub-id></mixed-citation></ref><ref id="pone.0210937.ref022"><label>22</label><mixed-citation publication-type="book"><chapter-title>Definitions and reporting framework for tuberculosis&#x02013; 2013 revision</chapter-title>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>, <year>2013</year> Available from.<ext-link ext-link-type="uri" xlink:href="http://www.who.int/tb/publications/definitions">http://www.who.int/tb/publications/definitions</ext-link></mixed-citation></ref><ref id="pone.0210937.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Sant&#x02019;Anna</surname><given-names>CC</given-names></name>, <name><surname>Schmidt</surname><given-names>CM</given-names></name>, <name><surname>March</surname><given-names>MdFBP</given-names></name>, <name><surname>Pereira</surname><given-names>SM</given-names></name>, <name><surname>Barreto</surname><given-names>ML</given-names></name>. <article-title>Tuberculose em adolescentes em duas capitais brasileiras</article-title>. <source>cad sa&#x000fa;de p&#x000fa;blica</source>. <month>1</month>
<year>2013</year>;<volume>29</volume>(<issue>1</issue>):<fpage>111</fpage>&#x02013;<lpage>6</lpage>.Portuguese <?supplied-pmid 23370030?><pub-id pub-id-type="pmid">23370030</pub-id></mixed-citation></ref><ref id="pone.0210937.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Crispim</surname><given-names>LC</given-names></name>, <name><surname>de Oliveira</surname><given-names>AM</given-names></name>, <name><surname>de Abreu</surname><given-names>W</given-names></name>. <article-title>Perfil epidemiol&#x000f3;gico de crian&#x000e7;as e adolescentes diagnosticados com tuberculose no Centro de Refer&#x000ea;ncia Augusto Guimar&#x000e3;es no per&#x000ed;odo de 2008 a 2012</article-title>. <source>Revista Cient&#x000ed;fica da FMC</source>. <month>5</month>
<year>2014</year>;<volume>9</volume>(<issue>1</issue>).Portuguese</mixed-citation></ref><ref id="pone.0210937.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Kaushik</surname><given-names>SL</given-names></name>, <name><surname>Krishnamurthy</surname><given-names>S</given-names></name>, <name><surname>Grover</surname><given-names>N</given-names></name>, <name><surname>Kaushik</surname><given-names>R</given-names></name>. <article-title>Spectrum Of Adolescent Tuberculosis in a Tertiary Care Hospital at Shimla, North India</article-title>. <source>Ann Appl Biosci</source>. <year>2016</year>;<volume>3</volume>(<issue>4</issue>):<fpage>A296</fpage>&#x02013;<lpage>300</lpage>.</mixed-citation></ref><ref id="pone.0210937.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Lotfian</surname><given-names>F</given-names></name>, <name><surname>Bolursaz</surname><given-names>MR</given-names></name>, <name><surname>Khalilzadeh</surname><given-names>S</given-names></name>, <name><surname>Baghaie</surname><given-names>N</given-names></name>, <name><surname>Hassanzad</surname><given-names>M</given-names></name>, <name><surname>Velayati</surname><given-names>A</given-names></name>. <article-title>Features of Adolescents Tuberculosis at a Referral TB&#x02019;s Hospital in Tehran, Iran</article-title>. <source>Mediterr J Hematol Infect Dis</source>. <year>2016</year>;<volume>8</volume>(<issue>1</issue>). <pub-id pub-id-type="doi">10.4084/MJHID.2016.005</pub-id>
<?supplied-pmid 26740866?><pub-id pub-id-type="pmid">26740866</pub-id></mixed-citation></ref><ref id="pone.0210937.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Poroor</surname><given-names>J</given-names></name>, <name><surname>George</surname><given-names>D</given-names></name>. <article-title>Tuberculosis in Adolescents and Children: Data on Clinical Presentation and Treatment Outcomes for a Period of 4 Years, from a tertiary care hospital in South India</article-title>. <source>J Evid-Based Med Hlthc</source>. <volume>2</volume>(<issue>18</issue>):<fpage>2752</fpage>&#x02013;<lpage>7</lpage>.;</mixed-citation></ref><ref id="pone.0210937.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Enane</surname><given-names>L</given-names></name>, <name><surname>Lowenthal</surname><given-names>E</given-names></name>, <name><surname>Arscott-Mills</surname><given-names>T</given-names></name>, <name><surname>Matlhare</surname><given-names>M</given-names></name>, <name><surname>Smallcomb</surname><given-names>L</given-names></name>, <name><surname>Kgwaadira</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2016</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1320</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.16.0060</pub-id>
<?supplied-pmid 27725042?><pub-id pub-id-type="pmid">27725042</pub-id></mixed-citation></ref><ref id="pone.0210937.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Fair</surname><given-names>CD</given-names></name>, <name><surname>Sullivan</surname><given-names>K</given-names></name>, <name><surname>Dizney</surname><given-names>R</given-names></name>, <name><surname>Stackpole</surname><given-names>A</given-names></name>. <article-title>&#x0201c;It's like losing a part of my family&#x0201d;: transition expectations of adolescents living with perinatally acquired HIV and their guardians</article-title>. <source>AIDS Patient Care STDS</source>. <year>2012</year>;<volume>26</volume>(<issue>7</issue>):<fpage>423</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/apc.2012.0041</pub-id>
<?supplied-pmid 22686235?><pub-id pub-id-type="pmid">22686235</pub-id></mixed-citation></ref><ref id="pone.0210937.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Greenley</surname><given-names>RN</given-names></name>, <name><surname>Kunz</surname><given-names>JH</given-names></name>, <name><surname>Biank</surname><given-names>V</given-names></name>, <name><surname>Martinez</surname><given-names>A</given-names></name>, <name><surname>Miranda</surname><given-names>A</given-names></name>, <name><surname>Noe</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Identifying youth nonadherence in clinical settings: data&#x02010;based recommendations for children and adolescents with inflammatory bowel disease</article-title>. <source>Inflamm Bowel Dis</source>. <year>2012</year>;<volume>18</volume>(<issue>7</issue>):<fpage>1254</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/ibd.21859</pub-id>
<?supplied-pmid 22689633?><pub-id pub-id-type="pmid">22689633</pub-id></mixed-citation></ref><ref id="pone.0210937.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Hodgson</surname><given-names>I</given-names></name>, <name><surname>Ross</surname><given-names>J</given-names></name>, <name><surname>Haamujompa</surname><given-names>C</given-names></name>, <name><surname>Gitau-Mburu</surname><given-names>D</given-names></name>. <article-title>Living as an adolescent with HIV in Zambia&#x02013;lived experiences, sexual health and reproductive needs</article-title>. <source>AIDS Care</source>. <year>2012</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1204</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1080/09540121.2012.658755</pub-id>
<?supplied-pmid 22380932?><pub-id pub-id-type="pmid">22380932</pub-id></mixed-citation></ref><ref id="pone.0210937.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Nichols</surname><given-names>SL</given-names></name>, <name><surname>Montepiedra</surname><given-names>G</given-names></name>, <name><surname>Farley</surname><given-names>JJ</given-names></name>, <name><surname>Sirois</surname><given-names>PA</given-names></name>, <name><surname>Malee</surname><given-names>K</given-names></name>, <name><surname>Kammerer</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>Cognitive, academic and behavioral correlates of medication adherence in children and adolescents with perinatally acquired HIV infection</article-title>. <source>J Dev Behav Pediatr</source>. <year>2012</year>;<volume>33</volume>(<issue>4</issue>):<fpage>298</fpage>
<pub-id pub-id-type="doi">10.1097/DBP.0b013e31824bef47</pub-id>
<?supplied-pmid 22366661?><pub-id pub-id-type="pmid">22366661</pub-id></mixed-citation></ref><ref id="pone.0210937.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Horton</surname><given-names>KC</given-names></name>, <name><surname>MacPherson</surname><given-names>P</given-names></name>, <name><surname>Houben</surname><given-names>RM</given-names></name>, <name><surname>White</surname><given-names>RG</given-names></name>, <name><surname>Corbett</surname><given-names>EL</given-names></name>. <article-title>Sex Differences in Tuberculosis Burden and Notifications in Low-and Middle-Income Countries: A Systematic Review and Meta-analysis</article-title>. <source>PLoS Med</source>. <year>2016</year>;<volume>13</volume>(<issue>9</issue>):<fpage>e1002119</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pmed.1002119</pub-id>
<?supplied-pmid 27598345?><pub-id pub-id-type="pmid">27598345</pub-id></mixed-citation></ref><ref id="pone.0210937.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>McKinnon</surname><given-names>LR</given-names></name>, <name><surname>Karim</surname><given-names>QA</given-names></name>. <article-title>Factors Driving the HIV Epidemic in Southern Africa</article-title>. <source>Curr HIV/AIDS Rep</source>. <year>2016</year>:<fpage>1</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/s11904-016-0296-x</pub-id><pub-id pub-id-type="pmid">26781112</pub-id></mixed-citation></ref><ref id="pone.0210937.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>C</given-names></name>, <name><surname>Hausler</surname><given-names>H</given-names></name>, <name><surname>Nunn</surname><given-names>P</given-names></name>. <article-title>A review of sex differences in the epidemiology of tuberculosis</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>1998</year>;<volume>2</volume>(<issue>2</issue>):<fpage>96</fpage>&#x02013;<lpage>104</lpage>. <?supplied-pmid 9562118?><pub-id pub-id-type="pmid">9562118</pub-id></mixed-citation></ref><ref id="pone.0210937.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Horton</surname><given-names>KC</given-names></name>, <name><surname>Houben</surname><given-names>RM</given-names></name>, <name><surname>White</surname><given-names>RG</given-names></name>, <name><surname>Corbett</surname><given-names>EL</given-names></name>. <article-title>Time for men to count, too</article-title>. <source>Int J Tuberc Lung Dis</source>. <year>2016</year>;<volume>20</volume>(<issue>3</issue>):<fpage>425</fpage>&#x02013;. <pub-id pub-id-type="doi">10.5588/ijtld.15.1031</pub-id>
<?supplied-pmid 27046729?><pub-id pub-id-type="pmid">27046729</pub-id></mixed-citation></ref></ref-list></back></article>